Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations
Sign Up to like & getrecommendations! Published in 2024 at "International Journal of Gynecological Pathology"
DOI: 10.1097/pgp.0000000000001050
Abstract: Targeted anti-HER2 therapy has been recently added to the standard treatment recommendations in endometrial serous carcinoma. Current eligibility requires testing for HER2 overexpression and/or gene amplification by immunohistochemistry and by fluorescence in situ hybridization. However,… read more here.
Keywords: immunohistochemical molecular; erbb2 her2; pathology; her2 ... See more keywords